H.R. 9418, Medicare Coverage Appeal Mechanism. Quorum's AI analysis reads it as a trade-off: gains for some, costs for others.
H.R. 9418 · Mixed
What it does
This bill creates a formal review process allowing drugmakers and others to challenge Medicare's decisions to deny or limit coverage of FDA-approved drugs. When a drug is approved by the FDA but Medicare refuses to cover it nationally, the bill requires Medicare to review the decision within 90 days, hold a 30-day public comment period, and issue a final decision within 120 days—with Medicare required to explain its reasoning and release clinical evidence if it reverses course. The bill also prevents Medicare from applying old coverage denials to newly approved drugs and blocks Medicare Part D plans from using outdated national coverage denials when deciding whether to cover a drug.
The analysis names pharmaceutical manufacturers — and 2 more groups — among the beneficiaries.
The trade-off
The 90-120 day review timeline may be too compressed for rigorous clinical evidence review, potentially forcing Medicare to approve drugs on limited data to meet the deadline.
The analysis put a high warning level on this bill. Transparency scores 72%, and the analysis found no provisions unrelated to the bill's subject.
Who is behind it
Filed by Nanette Barragán. Cosponsored by John Joyce.